Company profile: GRI Bio
1.1 - Company Overview
Company description
- Provider of therapies for inflammatory and autoimmune diseases, including GRI-0621, an oral inhibitor of iNKT cell activity for idiopathic pulmonary fibrosis, and GRI-0803, a novel activator of human type 2 NKT cells for autoimmune disorders with an initial focus on systemic lupus erythematosus, supported by a proprietary library of over 500 compounds.
Products and services
- GRI-0803: Novel activator of human type 2 NKT cells, architected to treat autoimmune disorders with initial emphasis on systemic lupus erythematosus
- GRI-0621: Oral, therapeutic inhibitor of invariant natural killer T (iNKT) cell activity, engineered to treat idiopathic pulmonary fibrosis through targeted immunomodulation
- Proprietary Compound Library: Proprietary collection of over 500 proprietary compounds used to develop new therapies targeting inflammatory diseases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to GRI Bio
Callidus Biopharma
HQ: United States
Website
- Description: Provider of drug discovery focused on best-in-class enzyme replacement therapies for lysosomal storage disorders, using a novel technology platform that attaches a form of naturally occurring Insulin-like Growth Factor (IGF-2) to therapeutic enzymes to enhance targeting to relevant cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Callidus Biopharma company profile →
Altimmune
HQ: United States
Website
- Description: Provider of vaccines and other biological products to address unmet market and public health needs, using proprietary non-invasive intranasal delivery to stimulate robust and durable immune responses for prevention; programs include pemvidutide, a GLP-1/glucagon dual receptor agonist being developed for obesity and for metabolic dysfunction-associated steatohepatitis (MASH). Proof of principle shown in animals and initial human clinical studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Altimmune company profile →
Affymax
HQ: United States
Website
- Description: Provider of biopharmaceutical solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Affymax company profile →
Inversago Pharma
HQ: Canada
Website
- Description: Provider of clinical-stage biotech therapies based on peripherally-acting CB1 inverse agonists, including INV-202, a small molecule CB1 receptor blocker for metabolic disorders in Phase 2 studies for diabetic kidney disease and obesity, and INV-347, a next-generation oral CB1 receptor blocker in Phase 1 evaluating safety, tolerability, and pharmacokinetics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inversago Pharma company profile →
Omthera
HQ: United States
Website
- Description: Provider of specialty pharmaceutical therapies in clinical development for dyslipidemia and elevated triglyceride levels, serving patients at increased risk of cardiovascular disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Omthera company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for GRI Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to GRI Bio
2.2 - Growth funds investing in similar companies to GRI Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for GRI Bio
4.2 - Public trading comparable groups for GRI Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →